Pretreatment serum albumin-to-alkaline phosphatase ratio is an independent prognosticator of survival in patients with metastatic gastric cancer

BACKGROUND Previous studies have suggested that a low albumin-to-alkaline phosphatase ratio (AAPR) is associated with a lower survival rate in patients with various malignancies. However, the relationship between pretreatment AAPR and the prognosis of patients with gastric cancer (GC) remains unclear. AIM To investigate the prognostic value of AAPR in distant metastatic GC. METHODS A total of 191 patients with distant metastatic cancer from a single institute were enrolled in this study. Pretreatment clinical data, including serum albumin and alkaline phosphatase levels, were collected. A chi-square test or Fisher’s exact test was applied to evaluate the correlations between AAPR and various clinical parameters in GC patients. The Kaplan–Meier method and Cox proportional hazards regression model were used to evaluate the prognostic efficacy of AAPR in metastatic GC patients. A two-sided P value lower than 0.05 was considered statistically significant. RESULTS A receiver operating characteristic curve indicated that 0.48 was the optimal threshold value for AAPR. AAPR ≤ 0.48 was significantly associated with bone (P < 0.05) and liver metastasis (P < 0.05). Patients with high levels of AAPR had better survival in terms of overall survival (OS) and progression-free survival (PFS), regardless of the presence of liver/bone metastasis. Pretreatment AAPR was found to be a favorable predictor of OS and PFS based on a multivariate cox regression model. AAPR-M system, constructed based on AAPR and number of metastatic sites, showed superior predictive ability relative to the number of metastatic sites for predicting survival. CONCLUSION Pretreatment AAPR may serve as an independent prognostic factor for predicting PFS and OS in patients with metastatic GC. Furthermore, AAPR may assist clinicians with individualizing treatment.

[1]  Yan Wang,et al.  Decreased albumin-to-alkaline phosphatase ratio predicted poor survival of resectable gastric cancer patients. , 2021, Journal of gastrointestinal oncology.

[2]  Hailun Xie,et al.  Prognostic Value of Pretreatment Albumin-to-Alkaline Phosphatase Ratio in Cancer: A Meta-Analysis , 2020, BioMed research international.

[3]  Xiaoli Guo,et al.  Prognostic effect of pretreatment albumin-to-alkaline phosphatase ratio in human cancers: A meta-analysis , 2020, PloS one.

[4]  Yue Yang,et al.  Pretreatment albumin-to-alkaline phosphatase ratio as a prognostic indicator in solid Cancers: A meta-Analysis with trial sequential analysis. , 2020, International journal of surgery.

[5]  Wei Jiang,et al.  Predictive value of pretreatment albumin‐to‐alkaline phosphatase ratio for overall survival for patients with advanced non‐small cell lung cancer , 2020, Cancer medicine.

[6]  Meng-Xin Tian,et al.  Albumin-to-Alkaline Phosphatase Ratio is an Independent Prognostic Indicator in Combined Hepatocellular and Cholangiocarcinoma , 2020, Journal of Cancer.

[7]  Feifei Li,et al.  Albumin-to-Alkaline Phosphatase Ratio Associates with Good Prognosis of Hepatitis B Virus-Positive HCC Patients , 2020, OncoTargets and therapy.

[8]  Lianyu Chen,et al.  Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis , 2020, BMC Cancer.

[9]  Wei-min Li,et al.  Albumin-to-alkaline phosphatase ratio at diagnosis predicts survival in patients with metastatic non-small-cell lung cancer , 2019, OncoTargets and therapy.

[10]  D. Heo,et al.  The Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio before Radical Radiotherapy in Patients with Non-metastatic Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis , 2019, Cancer research and treatment : official journal of Korean Cancer Association.

[11]  Jinming Yu,et al.  Prognostic value of dynamic albumin-to-alkaline phosphatase ratio in limited stage small-cell lung cancer. , 2019, Future oncology.

[12]  K. Hanazaki,et al.  Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer , 2018, Gastric Cancer.

[13]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[14]  Yongsheng Song,et al.  Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis , 2018, Cancer management and research.

[15]  Yan Zhang,et al.  Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer , 2018, Medicine.

[16]  Y. Teng,et al.  Pretreatment platelet‐to‐lymphocyte ratio is associated with the response to first‐line chemotherapy and survival in patients with metastatic gastric cancer , 2018, Journal of clinical laboratory analysis.

[17]  H. Weir,et al.  Liver cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study , 2017, Cancer.

[18]  Li Zhang,et al.  Clinical Characteristics and Prognostic Factors in Bone Metastases from Lung Cancer , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[19]  David K. Espey,et al.  Stomach cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study , 2017, Cancer.

[20]  Weidong Wei,et al.  Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer , 2016, Journal of Cancer.

[21]  Yun-zhao Chen,et al.  Preoperative Body Mass Index, Blood Albumin and Triglycerides Predict Survival for Patients with Gastric Cancer , 2016, PloS one.

[22]  Ken Kato,et al.  Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer , 2016, Journal of Cancer Research and Clinical Oncology.

[23]  V. Wong,et al.  Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma , 2015, Disease markers.

[24]  J. Barkin,et al.  Stomach , 2015, The American Journal of Gastroenterology.

[25]  S. Hong,et al.  Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis , 2014, Journal of Cancer Research and Clinical Oncology.

[26]  L. Helyer,et al.  Prognostic factors in metastatic gastric cancer: results of a population-based, retrospective cohort study in Ontario , 2014, Gastric Cancer.

[27]  F. Başak,et al.  CEA and CA 19-9 are still valuable markers for the prognosis of colorectal and gastric cancer patients. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[28]  J. Lee,et al.  The effect of alkaline phosphatase and intrahepatic metastases in large hepatocellular carcinoma , 2013, World Journal of Surgical Oncology.

[29]  N. Ohkohchi,et al.  Evaluation of serum high‐density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients , 2012, Journal of gastroenterology and hepatology.

[30]  Yun-Fei Xia,et al.  Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma , 2012, Chinese journal of cancer.

[31]  F. Lordick,et al.  Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) , 2010, British Journal of Cancer.

[32]  C. Shanahan,et al.  Role for alkaline phosphatase as an inducer of vascular calcification in renal failure? , 2008, Kidney international.

[33]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[34]  F. Otto,et al.  Gene deregulation in gastric cancer. , 2005, Gene.

[35]  W. Harb,et al.  The cancer cachexia syndrome: a review of metabolic and clinical manifestations. , 2005, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[36]  G. Barnett,et al.  Presurgical Serum Albumin Levels Predict Survival Time from Glioblastoma Multiforme , 1999, Journal of Neuro-Oncology.

[37]  L. Walker,et al.  Serum albumin: a prognostic indicator in patients with colorectal cancer. , 1998, Journal of the Royal College of Surgeons of Edinburgh.